Labgenomics Co

Labgenomics Co Goodwill/Assets

The Goodwill to Total Assets Ratio of Labgenomics Co (084650.KQ) as of Oct 26, 2026 is 24.15 %. In the previous year, Goodwill to Total Assets Ratio was 19.73 % — a change of 22.41% (higher).

Goodwill/Assets

24.15 %

YoY

22.41%

Last updated:

Goodwill to Total Assets Ratio of Labgenomics Co is 2025 24.15 % . Goodwill to Total Assets Ratio of Labgenomics Co was 2024 19.73 % . It decreases by 22.41% higher compared to the previous year.

The Labgenomics Co Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2018
0.00 KRW
Jan 1, 2019
0.00 KRW
Jan 1, 2020
0.00 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
17.51 KRW
Jan 1, 2024
19.73 KRW
Jan 1, 2025
24.15 KRW
The Labgenomics Co Goodwill/Assets history
YEARGoodwill/AssetsYoY
24.15 %+22.41%
19.73 %+12.66%
17.51 %+4.39 B%
0.00-18.50%
0.00-46.47%
0.00-54.76%
0.00-4.82%
0.00-15.34%
0.00+8.39%
0.00-26.67%
0.00-1.87%
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Goodwill to Total Assets Ratio of Labgenomics Co is 24.15 % in 2025.

Goodwill to Total Assets Ratio of Labgenomics Co changed from 19.73 % to 24.15 %, representing a 22.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Labgenomics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labgenomics Co

All Key Metrics — Labgenomics Co